ClinicalTrials.gg
CompletedNCT04815551Updated Jun 12, 2023

A Phase 1 Study of AV-380 in Healthy Subjects

A Phase 1 interventional study of AV-380 and Placebo in Cachexia, sponsored by AVEO Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-12.

Sponsored by AVEO Pharmaceuticals, Inc. (part of LG Chem) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2022, 4 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Cachexia with a site in United States — 9 open to participants now, 11 under way, 2 of them phase 3. Cachexia · United States.

Enrollment
36th of 72
51 · median 51
Started
2021
with 2 others
Phase 1
21 of 95
2 open now
Registered
76th of 95
by date

Among the 95 studies in Cachexia with a site in United States, this one is the 36th largest by enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2021, is one of 21 in phase 1, and was the 76th registered.

Cachexia

331 studies on the registry are indexed under Cachexia; 74 are open to participants now.

Browse Cachexia studies →

Open to participants now

9 of the 95 studies in Cachexia with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Cachexia with a site in United States, or all of them as a file.
02

Study summary

This double-blinded, placebo-controlled, single ascending dose (SAD) study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity in healthy subjects of a single dose of AV-380. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

03

Conditions studied

  • Cachexia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female volunteers, 18 to 50 years of age, inclusive.
  2. A (BMI) between 18 and 30 kg/m2 and weight between 60 and 90 kg.
  3. Healthy as indicated by a comprehensive clinical assessment (detailed medical history and complete physical examination). Supine blood pressure (BP), heart rate (HR), (ECG) intervals and routine laboratory tests within the normal range of the study center (see Appendix 4) or considered not by the Investigator. (ALT), aspartate aminotransferase (AST), and total must be \< 1.5 times the (ULN). Total bilirubin, if above 1.5 x ULN, is only acceptable with a history of Gilbert's Syndrome.
  4. Non-smoker or ex-smoker for longer than 6 months.
  5. Sexually active pre-menopausal female subjects and female partners of male subjects must use adequate measures, while on study and for at least 100 days after the IMP administration. Sexually active male subjects must use adequate contraceptive measures, while on study and for at least 160 days after the last dose of IMP. All fertile male and female subjects and their partners must agree to use a highly effective method of contraception. Effective birth control includes hormonal contraception (oral, intravaginal, transdermal, injectable or implantable), intrauterine device (IUD) plus one barrier method; or 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). Vasectomy (at least 3 months before IMP administration) and vasectomized partner (provided that the partner is the sole sexual partner of the trial participant and that the absence of sperm in the ejaculate has been confirmed) are acceptable methods of contraception, as well as female for at least 1 year (confirmed with serum follicle stimulating hormone [FSH] > 25.8 IU/L at screening), or surgically sterilized female subjects. Abstinence is not an acceptable contraception method. Female subjects who are of non- due to a surgical procedure or medical condition must provide documentation, and vasectomized male subjects must bring in the surgical report of the procedure.
  6. Able to sign and understand an ICF and able to comply with study restrictions prior to selection.

Exclusion criteria

Exclusion Criteria:

  1. Presence or history of any disorder that may prevent the successful completion of the study.
  2. abnormalities in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis), such as:

    • White blood cell count \< 3.0x109/L.
    • Neutrophils \< 1.5x109/L or clinically abnormal according to the subject's ethnic group (must be > 1.0x109/L for subjects of African descent).
    • \< 10 g/dL.
    • count \< 125x109/L or > 450x109/L.
    • > 1.5 .
    • AST > 1.5 ULN.
    • Total > 1.5 ULN (except in the presence of Gilbert's syndrome).
    • Creatinine > 1.2 ULN.
    • Sodium \< 132 mmol/L or > 147 mmol/L.
    • Potassium \< 3.2 mmol/L or > 5.5 mmol/L.
    • Chloride \< 93 mmol/L or > 111 mmol/L.
    • Calcium \< 8.3 mmol/L or > 10.7 mmol/L. Clinically significant abnormal values for all other laboratory parameters are at the investigator's discretion.
  3. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the medicine product.
  4. Any history of drug related reaction.
  5. Prior treatment with a monoclonal antibody.
  6. Intercurrent illness as evidenced by, e.g., nausea, vomiting, fever, or diarrhea) within 7 days before D1.
  7. History of drug abuse (habitual taking of addictive or illegal drugs) within 1 year before D1.
  8. Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or soda) or grapefruit-containing products or alcoholic beverages within 48 hours before D1 and until D7.
  9. Any condition or disease detected during the medical interview / physical examination that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the Investigator or his designee.
  10. Frequent headaches and/or migraine, recurrent nausea and / or vomiting.
  11. Female subjects who are pregnant, or breastfeeding.
  12. Positive screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, phencyclidine [PCP]) and breath alcohol test at screening or D-2.
  13. Positive serology for or or human immunodeficiency viruses ().
  14. Positive SARS-CoV-2 RT-PCR.
  15. Any condition detected at screening that may interfere with or bias the physical examinations to be performed during the study.
  16. Any prescribed or over-the-counter medication or herbal products taken within 1 week prior to start of administration of IMP (D1) or within 6 times the elimination half-life of the medication prior to start of IMP intake (whichever is longer), except as described in inclusion criterion number 5 in Section 6.1. Vitamin/mineral supplements and occasional use of acetaminophen is allowed up until 24 hours before dosing.
  17. Participation in a clinical trial or use of an investigational drug within 30 days before randomization.
  18. Any vaccination within 30 days before signature of .
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    AV-380 IV 4 mg/kg

    IV infusion of AV-380 at dose level 4 mg/kg

    Drug: AV-380

  • Experimental
    AV-380 IV 8 mg/kg

    IV infusion of AV-380 at dose level 8 mg/kg

    Drug: AV-380

  • Experimental
    AV-380 IV 13 mg/kg

    IV infusion of AV-380 at dose level 13 mg/kg

    Drug: AV-380

  • Experimental
    AV-380 IV 20 mg/kg

    IV infusion of AV-380 at dose level 20 mg/kg

    Drug: AV-380

  • Experimental
    AV-380 SC 4 mg/kg

    Subcutaneous injection of AV-380 at dose level 4 mg/kg

    Drug: AV-380

  • Experimental
    AV-380 SC 2 mg/kg

    Subcutaneous injection of AV-380 at dose level 2 mg/kg

    Drug: AV-380

  • Experimental
    AV-380 SC 1 mg/kg

    Subcutaneous injection of AV-380 at dose level 1 mg/kg

    Drug: AV-380

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugAV-380

    AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

  • DrugPlacebo

    Placebo is sterile liquid for IV infusion.

06

What researchers measure

Primary outcomes

  1. Assessment of adverse events (AEs) and treatment emergent adverse events (TEAEs)

    Time frame: Through study completion, an average of 60 days

  2. Injection site safety and tolerability assessment

    Site injection tolerability will be assessed by the Investigator using a 4-level score (none, mild, moderate, severe) after IV infusion and SC injection.

    Time frame: Visit Day 1

  3. Clinical laboratory measurements - Hematology - hemoglobin

    Hemoglobin (g/dL)

    Time frame: Visits Day 1 through Day 60

  4. Clinical laboratory measurements - Hematology - hematocrit

    Hematocrit (%)

    Time frame: Visits Day 1 through Day 60

  5. Clinical laboratory measurements - Hematology - erythrocytes

    Erythrocytes

    Time frame: Visits Day 1 through Day 60

  6. Clinical laboratory measurements - Hematology - white blood cell count

    White blood cell count with differential (neutrophils, basophils, eosinophils, lymphocytes, monocytes and platelets) (X10(3)/UL)

    Time frame: Visits Day 1 through Day 60

  7. Clinical laboratory measurements - Blood chemistry - sodium

    Sodium (mmol/L)

    Time frame: Visits Day 1 through Day 60

  8. Clinical laboratory measurements - Blood chemistry - potassium

    Potassium (mmol/L)

    Time frame: Visits Day 1 through Day 60

  9. Clinical laboratory measurements - Blood chemistry - calcium

    Calcium (mg/dL)

    Time frame: Visits Day 1 through Day 60

  10. Clinical laboratory measurements - Blood chemistry - chloride

    Chloride (mmol/L)

    Time frame: Visits Day 1 through Day 60

  11. Clinical laboratory measurements - Blood chemistry - CO2

    CO2 (mmol/L)

    Time frame: Visits Day 1 through Day 60

  12. Clinical laboratory measurements - Blood chemistry - blood urea nitrogen

    Blood urea nitrogen (mg/dl)

    Time frame: Visits Day 1 through Day 60

  13. Clinical laboratory measurements - Blood chemistry - creatinine

    creatinine (mg/dL), glucose, total proteins, triglycerides, total cholesterol, AST, ALT, gamma-glutamyltransferase, creatinine phosphokinase, albumin, alkaline phosphatase, and total bilirubin

    Time frame: Visits Day 1 through Day 60

  14. Clinical laboratory measurements - Blood chemistry - glucose

    Glucose (mg/dL)

    Time frame: Visits Day 1 through Day 60

  15. Clinical laboratory measurements - Blood chemistry - total proteins

    Total proteins (g/dL), triglycerides, total cholesterol, AST, ALT, gamma-glutamyltransferase, creatinine phosphokinase, albumin, alkaline phosphatase, and total bilirubin

    Time frame: Visits Day 1 through Day 60

  16. Clinical laboratory measurements - Blood chemistry - triglycerides

    Triglycerides (mg/dL)

    Time frame: Visits Day 1 through Day 60

  17. Clinical laboratory measurements - Blood chemistry - total cholesterol

    Total cholesterol (mg/dL)

    Time frame: Visits Day 1 through Day 60

  18. Clinical laboratory measurements - Blood chemistry - AST

    AST (U/L)

    Time frame: Visits Day 1 through Day 60

  19. Clinical laboratory measurements - Blood chemistry - ALT

    ALT (U/L)

    Time frame: Visits Day 1 through Day 60

  20. Clinical laboratory measurements - Blood chemistry - Gamma-glutamyltransferase

    Gamma-glutamyltransferase (U/L)

    Time frame: Visits Day 1 through Day 60

  21. Clinical laboratory measurements - Blood chemistry - Creatinine phosphokinase

    Creatinine phosphokinase (mg/dL)

    Time frame: Visits Day 1 through Day 60

  22. Clinical laboratory measurements - Blood chemistry - albumin

    Albumin (g/dL)

    Time frame: Visits Day 1 through Day 60

  23. Clinical laboratory measurements - Blood chemistry - alkaline phosphatase

    Alkaline phosphatase (U/L)

    Time frame: Visits Day 1 through Day 60

  24. Clinical laboratory measurements - Blood chemistry - total bilirubin

    Total bilirubin (mg/dl)

    Time frame: Visits Day 1 through Day 60

  25. Clinical laboratory measurements - Coagulation - partial thromboplastin time

    Activated partial thromboplastin time (secs)

    Time frame: Visits Day 1 through Day 60

  26. Clinical laboratory measurements - Coagulation - prothrombin time

    Prothrombin time (sec)

    Time frame: Visits Day 1 through Day 60

  27. Clinical laboratory measurements - Coagulation - International normalized ratio

    International normalized ratio

    Time frame: Visits Day 1 through Day 60

  28. Clinical laboratory measurements - Hormonology

    Measured parameters: Hormonology (TSH, FSH (for post-menopausal women); β-HCG (for women of childbearing potential))

    Time frame: Visits Day 1 through Day 90

  29. Clinical laboratory measurements - Hormonology - TSH

    TSH (mIU/mL)

    Time frame: Visits Day 1 through Day 90

  30. Clinical laboratory measurements - Hormonology - FSH

    FSH (mIU/mL)

    Time frame: Visits Day 1 through Day 90

  31. Clinical laboratory measurements - Urinalysis - pH

    pH

    Time frame: Visits Day 1 through Day 60

  32. Clinical laboratory measurements - Urinalysis - protein

    Protein (negative/positive)

    Time frame: Visits Day 1 through Day 60

  33. Clinical laboratory measurements - Urinalysis - glucose

    Glucose (negative/positive)

    Time frame: Visits Day 1 through Day 60

  34. Clinical laboratory measurements - Urinalysis - leukocytes

    Leukocytes (negative/positive)

    Time frame: Visits Day 1 through Day 60

  35. Clinical laboratory measurements - Urinalysis - nitrites

    Nitrites (negative/positive)

    Time frame: Visits Day 1 through Day 60

  36. Clinical laboratory measurements - Urinalysis - ketones

    Ketones (negative/positive)

    Time frame: Visits Day 1 through Day 60

  37. Clinical laboratory measurements - Urinalysis - blood

    Blood (negative/positive)

    Time frame: Visits Day 1 through Day 60

  38. Vital signs measurements - Blood pressure

    Supine and standing systolic and diastolic blood pressure (mmHg)

    Time frame: Visits Day 1 through Day 90

  39. Vital signs measurements - Heart rate

    Heart rate (beats/min)

    Time frame: Visits Day 1 through Day 90

  40. Vital signs measurements - Body temperature

    Body temperature (degrees Celsius)

    Time frame: Visits Day 1 through Day 90

  41. Vital signs measurements - Respiratory rate

    Respiratory rate (breaths/min)

    Time frame: Visits Day 1 through Day 90

  42. Electrocardiogram (ECG) measurements - Mean heart rate

    ECG mean heart rate (beats/min)

    Time frame: Visits Day 1 through Day 90

  43. Electrocardiogram (ECG) measurements - PR interval

    PR interval, aggregate (msec)

    Time frame: Visits Day 1 through Day 90

  44. Electrocardiogram (ECG) measurements - QRS axis

    QRS axis (deg)

    Time frame: Visits Day 1 through Day 90

  45. Electrocardiogram (ECG) measurements - QTcF interval

    QTcF interval, aggregate (msec)

    Time frame: Visits Day 1 through Day 90

Secondary outcomes

  1. Serum PK of single dose AV-380 via intravenous infusion and subcutaneous injection

    Cmax (maximum observed serum concentration)

    Time frame: Visits Day 1 through D90

  2. Serum PK of single dose AV-380 via intravenous infusion and subcutaneous injection

    Tmax (time to reach maximum serum concentration)

    Time frame: Visits Day 1 through Day 90

  3. To correlate the serum level of GDF-15 with the dose and serum level of AV-380

    Emax (maximum effect observed)

    Time frame: Visits Day 1 through Day 90

  4. To correlate the serum level of GDF-15 with the dose and serum level of AV-380

    AUEC (area under the effect-time curve)

    Time frame: Visits Day 1 through Day 90

  5. To correlate the serum level of GDF-15 with the dose and serum level of AV-380

    TEmax (time to reach maximum effect)

    Time frame: Visits Day 1 through Day 90

  6. AV-380 immunogenicity in healthy subjects - anti-AV-380 antibodies (human anti-human antibodies [HAHA]) levels in serum.

    HAHA levels

    Time frame: Visits Day 1 through Day 180

  7. AV-380 immunogenicity in healthy subjects - Monocyte chemoattractant protein 1 (MCP-1) levels in serum.

    Serum MCP-1 levels will be measured.

    Time frame: Visits Day 1 and Day 2

07

Study locations

1 site
  • Biotrial Inc.
    Newark, New Jersey 07103, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jan 2022, 10 months.

Of 21 phase 1 interventional studies under Cachexia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 10 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2021
First posted
Mar 25, 2021
StartActual
Feb 22, 2021
Primary completionActual
Jan 14, 2022
CompletionActual
Jan 14, 2022
Last update
Jun 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04815551
Responsible party
Sponsor
First posted
Mar 25, 2021
Start date
Feb 22, 2021
Primary completion
Jan 14, 2022
Completion
Jan 14, 2022
Last update
Jun 12, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilogrotug

Start the discussion